## DVA: DaVita Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.16 indicates fundamental undervaluation. Quality metrics strong (ROE 62%). Caution: momentum weakening (-4.8% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($109.68)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 7
- **Sentiment:** Neutral (Bullish: 2, Bearish: 0)

**1. DaVita Inc. Stock Underperforms Thursday When Compared To Competitors**
- Source: 富途牛牛 | 20251219T140818 | Somewhat-Bearish | Relevance: 100%
- DaVita Inc. stock underperformed on Thursday compared to its competitors. The article briefly mentions Unity Software's fourth-quarter financial results, noting a significant year-over-year revenue increase and a reported quarterly loss. It appears the initial headline was intended for an article focusing on DaVita, but the content shared instead pertains to Unity Software's earnings.

**2. Here's Why You Should Hold DaVita Stock in Your Portfolio for Now**
- Source: Finviz | 20251218T152659 | Neutral | Relevance: 100%
- DaVita Inc. (DVA) is a Zacks Rank #3 (Hold) stock gaining from its patient-centric business model and international expansion, despite a recent 12.8% loss against industry growth. The company reported mixed third-quarter 2025 results with increased top-line and revenue per treatment, but faces challenges due to its dependence on commercial payers. DaVita projects 12.6% growth over the next five years and maintains a stable earnings estimate for 2025.

**3. How Leadership Changes At DaVita (DVA) Have Changed Its Investment Story**
- Source: Simply Wall Street | 20251217T130759 | Neutral | Relevance: 100%
- DaVita Inc. has recently appointed Stephanie Hendrickson as Chief People Officer and Steve Phillips as Chief Strategy Officer, signaling a focus on culture, patient care, and long-term strategy amidst operational and cost pressures. While these leadership changes are more cultural than immediately catalytic, the company's expanded credit facilities provide financial flexibility to manage elevated operating costs and cyber recovery spending. Investors should consider these developments alongside rising patient care costs and reimbursement risks, which continue to influence DaVita's investment narrative and profitability.

**4. Is There Now An Opportunity In DaVita Inc. (NYSE:DVA)?**
- Source: 富途牛牛 | 20251217T221020 | Bullish | Relevance: 100%
- DaVita Inc. (NYSE:DVA) has experienced significant price movements recently but is currently trading below its industry average based on its price-to-earnings ratio, suggesting it may be undervalued. With an expected profit growth of 23% over the next couple of years, the company shows a bright future outlook and potential for higher share valuation, making it an opportune time for investors to consider accumulating or buying the stock. However, potential investors should also assess the company's financial health and other risk factors.

**5. DaVita Inc. (NYSE:DVA) Given Average Rating of "Hold" by Brokerages**
- Source: MarketBeat | 20251217T130356 | Neutral | Relevance: 100%
- DaVita Inc. (NYSE:DVA) has received an average recommendation of "Hold" from eight brokerages, with the average twelve-month target price set at $148.00. The company recently reported earnings of $2.51 EPS, missing analyst estimates, and its stock is currently trading down by 1.7% at $118.00. Institutional investors hold a significant portion of the stock.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 4 ($55.95M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 69.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Berkshire Hathaway, : 45.6% (-4.8%)
- Vanguard Group Inc: 6.0% (-10.9%)
- Blackrock Inc.: 5.1% (-13.1%)
- State Street Corpora: 2.6% (-12.4%)
- Invesco Ltd.: 2.4% (+2.0%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.8% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $56M sold (4 transactions in 90 days).
3. High short interest (21.2%, 6.2 days to cover): squeeze risk or crowded bearish bet.
4. Long-term trend broken: trading 14.9% below SMA200.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.16 suggests fair value with growth premium. Forward P/E 9.0x attractive for 19% earnings growth. Quality metrics strong (ROE 62%). Insider selling cluster ($56.0M in 90 days), potential headwind. Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $8.2B |
| Beta | 0.99 |
| 52W Range | $113.97 - $179.60 |
| Short Interest | 21.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.16 |
| Forward P/E | 9.0 |
| Current P/E | 10.8 |
| YoY Growth | 19.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.5% to -3.3% (-4.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.3pp (needs >4.0% for momentum thesis). Underperforming sector by 3.2pp, stock-specific weakness. Below SMA200 (0.85x), long-term trend not supportive. OFD pattern: -DUH (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.28% (CS: 19) | Weak |
| RSI_14 | 37.7 | Neutral |
| MACD Histogram | -0.04 | Bearish |
| vs SMA20 | 0.970x | Below |
| vs SMA50 | 0.949x | Below |
| vs SMA200 | 0.851x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $115.20
- **Stop Loss:** $109.68 (4.8% risk)
- **Target:** $126.24 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 217
- **Position Value:** $24,998.40
- **Portfolio %:** 25.00%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-12 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.17 | $2.51 | -20.9% |
| 2025Q2 | $2.75 | $2.95 | +7.3% |
| 2025Q1 | $2.02 | $2.00 | -0.9% |
| 2024Q4 | $2.13 | $2.24 | +5.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*